Items Tagged ‘metastatic non-small cell lung cancer’

July 20th, 2015

FDA Approves Iressa for Treatment of Patients with Metastatic Non Small Cell Lung Cancer


The U. S. Food and Drug Administration approved IRESSA (gefitinib) for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test. Gefitinib is being approved concurrently with a labeling expansion of […]

View full entry

Tags: FDA approval, gefitinib, Lung Cancer - Non-Small Cell, metastatic non-small cell lung cancer, News, nsclc, Stages IIIB-IV Lung Cancer - Non-Small Cell